Collaborative pooled analysis of data on C-reactive protein gene variants and coronary disease: judging causality by Mendelian randomisation

Many prospective studies have reported associations between circulating C-reactive protein (CRP) levels and risk of coronary heart disease (CHD), but causality remains uncertain. Studies of CHD are being conducted that involve measurement of common polymorphisms of the CRP gene known to be associated with circulating concentrations, thereby utilising these variants as proxies for circulating CRP levels. By analysing data from several studies examining the association between relevant CRP polymorphisms and CHD risk, the present collaboration will undertake a Mendelian randomisation analysis to help assess the likelihood of any causal relevance of CRP levels to CHD risk. A central database is being established containing individual data on CRP polymorphisms, circulating CRP levels, and major coronary outcomes as well as age, sex and other relevant characteristics. Associations between CRP polymorphisms or haplotypes and CHD will be evaluated under different circumstances. This collaboration comprises, at present, about 37,000 CHD outcomes and about 120,000 controls, which should yield suitably precise findings to help judge causality. This work should advance understanding of the relevance of low-grade inflammation to CHD and indicate whether or not CRP itself is involved in long-term pathogenesis.

[1]  Paolo Vineis,et al.  A road map for efficient and reliable human genome epidemiology , 2006, Nature Genetics.

[2]  C. Sabin,et al.  Proinflammatory Effects of Bacterial Recombinant Human C-Reactive Protein Are Caused by Contamination With Bacterial Products, Not by C-Reactive Protein Itself , 2005, Circulation research.

[3]  Juan P Casas,et al.  Estimation of bias in nongenetic observational studies using "mendelian triangulation". , 2006, Annals of epidemiology.

[4]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[5]  Juan P Casas,et al.  Insight into the nature of the CRP-coronary event association using Mendelian randomization. , 2006, International journal of epidemiology.

[6]  Gary L Myers,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[7]  M. Rieder,et al.  Genetic Variation Is Associated With C-Reactive Protein Levels in the Third National Health and Nutrition Examination Survey , 2006, Circulation.

[8]  P. Ridker,et al.  Effect of statin therapy on C-reactive protein levels. The pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study☆ , 2001 .

[9]  J. Hokanson,et al.  Plasma Triglyceride Level is a Risk Factor for Cardiovascular Disease Independent of High-Density Lipoprotein Cholesterol Level: A Metaanalysis of Population-Based Prospective Studies , 1996, Journal of cardiovascular risk.

[10]  P. Ridker,et al.  C-reactive protein comes of age , 2005, Nature Clinical Practice Cardiovascular Medicine.

[11]  M. Rieder,et al.  Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein. , 2008, American journal of human genetics.

[12]  J. Giddings,et al.  C-Reactive Protein–Induced In Vitro Endothelial Cell Activation Is an Artefact Caused by Azide and Lipopolysaccharide , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[13]  E. Rimm,et al.  C-Reactive Protein (CRP) Gene Polymorphisms, CRP Levels, and Risk of Incident Coronary Heart Disease in Two Nested Case-Control Studies , 2008, PloS one.

[14]  H Tunstall-Pedoe,et al.  The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases , 2007, European Journal of Epidemiology.

[15]  Y. Hattori,et al.  Vascular smooth muscle cell activation by C-reactive protein. , 2003, Cardiovascular research.

[16]  Sidney C. Smith,et al.  MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: APPLICATION TO CLINICAL AND PUBLIC HEALTH PRACTICE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE AMERICAN HEART ASSOCIATION , 2003 .

[17]  P. Ridker,et al.  Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. , 2002, Atherosclerosis.

[18]  Tom R. Gaunt,et al.  C-reactive protein and its role in metabolic syndrome: mendelian randomisation study , 2005, The Lancet.

[19]  G. Lowe,et al.  Interleukin-6, Fibrin D-Dimer, and Coagulation Factors VII and XIIa in Prediction of Coronary Heart Disease , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[20]  A. Hingorani,et al.  Nature's randomised trials , 2005, The Lancet.

[21]  A. Hofman,et al.  C-reactive protein gene haplotypes and risk of coronary heart disease: the Rotterdam Study. , 2006, European heart journal.

[22]  Mark B Pepys,et al.  C-reactive protein: a critical update. , 2003, The Journal of clinical investigation.

[23]  L. Kuller,et al.  Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. , 1996, American journal of epidemiology.

[24]  C. Carlson,et al.  Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. , 2006, JAMA.

[25]  E. Paffen,et al.  C-reactive protein in atherosclerosis: A causal factor? , 2006, Cardiovascular research.

[26]  J. Danesh,et al.  Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses , 2000, BMJ : British Medical Journal.

[27]  L. Smeeth,et al.  For Personal Use. Only Reproduce with Permission from Elsevier Ltd Homocysteine and Stroke: Evidence on a Causal Link from Mendelian Randomisation , 2022 .

[28]  Bernard Keavney,et al.  Genetic epidemiological studies of coronary heart disease. , 2002, International journal of epidemiology.

[29]  John P. A. Ioannidis,et al.  The Emergence of Networks in Human Genome Epidemiology: Challenges and Opportunities , 2007, Epidemiology.

[30]  M. Pencina,et al.  C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. , 2005, Archives of internal medicine.

[31]  N. Sheehan,et al.  Mendelian randomization as an instrumental variable approach to causal inference , 2007, Statistical methods in medical research.

[32]  Vilmundur Gudnason,et al.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.

[33]  Claudio J. Verzilli,et al.  Bayesian meta-analysis of genetic association studies with different sets of markers. , 2007, American journal of human genetics.

[34]  J. Danesh,et al.  Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies , 2000, Circulation.

[35]  S. Humphries,et al.  Human CRP Gene Polymorphism Influences CRP Levels: Implications for the Prediction and Pathogenesis of Coronary Heart Disease , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[36]  Ren-Ke Li,et al.  A Self-Fulfilling Prophecy: C-Reactive Protein Attenuates Nitric Oxide Production and Inhibits Angiogenesis , 2002, Circulation.

[37]  Steven V. Ley,et al.  Targeting C-reactive protein for the treatment of cardiovascular disease , 2006, Nature.

[38]  A. Hingorani,et al.  Linking observational and genetic approaches to determine the role of C-reactive protein in heart disease risk. , 2006, European heart journal.

[39]  S. Ebrahim,et al.  'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? , 2003, International journal of epidemiology.